2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report/Personnel Ad hoc announcement pursuant to Art. 53 LR July 26, 2024 BB Biotech AG publishes its interim report and announces a new head of its investment management team BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2024, which covers the results of its business activities for the first six months of 2024. Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2024, amounted to CHF 173 mn (loss of CHF 267 mn in H1 2023). In the second quarter a loss of CHF 87 mn (loss of CHF 13 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio. BB Biotech AG’s interim report as at June 30, 2024, is available under report.bbbiotech.ch/Q224 or www.bbbiotech.com.
Dr. Daniel Koller, who has served as head of BB Biotech’s investment management team since 2010, has informed the board of directors of his intention to retire from his position by the end of 2024. The board of directors has appointed Dr. Christian Koch, one of the two deputy heads, as the new head of the investment management team effective January 1, 2025.
Investor Relations Media Relations
www.bbbiotech.com Company profile End of Inside Information
26-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | info@bbbiotech.com |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 1954217 |
| End of Announcement | EQS News Service |
|
|
1954217 26-Jul-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
